Posluma (flotufolastat F 18) is an radiopharmaceutical imaging agent that helps providers see areas of prostate cancer on a specific test known as a prostate-specific membrane antigen – positron emission tomography (PSMA-PET) scan. It’s for people with prostate cancer that might have come back after initial treatment (recurrent) or spread (metastasized) to other parts of the body. It’s given as an infusion through the vein before the PET scan. Side effects include diarrhea, injection site pain, and a rise in blood pressure.
Diagnose suspected advanced prostate cancer, during a PSMA-PET scan
Posluma (flotufolastat F 18) is a radiopharmaceutical. It attaches to a particular protein found on the surface of certain cancer cells called prostate-specific membrane antigen (PSMA). Once attached, the radioactive portion of Posluma (flotufolastat F 18) lights up the areas with prostate cancer on a certain type of scan called a PSMA PET scan.
Diagnose suspected advanced prostate cancer, during a PSMA-PET scan
Men with treatable prostate cancer that might have spread to other organs
Men with a history of prostate cancer that has come back based on high levels of prostate-specific antigen (PSA)
Men with treatable prostate cancer that might have spread to other organs
Men with a history of prostate cancer that has come back based on high levels of prostate-specific antigen (PSA)
Men with prostate cancer that might have spread to other organs that is treatable by Pluvicto (lutetium Lu 177 vipivotide tetraxetan) - Locametz only
By providing your email, you consent to receive marketing communications from GoodRx, which may include content and/or data related to men’s health, women's health, reproductive care, or sexual health. You agree to the GoodRx Terms of Use and acknowledge the Privacy Policy. You can unsubscribe at any time.
Blue Earth Diagnostics. (2023). Posluma- flotufolastat f-18 injection [package insert]. DailyMed.
Chang, S. S. (2004). Overview of prostate-specific membrane antigen. Reviews in Urology.
Munjal, A., et al. (2023). Radiopharmaceuticals. StatPearls.
U.S. Food and Drug Administration. (2023). Novel drug approvals for 2023.
Research prescriptions and over-the-counter medications from A to Z, compare drug prices, and start saving.